19th August 2011
Celentyx founders Professor John Gordon & Professor Nicholas Barnes identify potential of modified Ecstasy as potent blood cancer treatment
Download pdf
15th October 2010
Professor John Gordon to present Raine Visiting Professor Lecture entitled:
The Emergence of ‘Neuro-Immuno-Pharmacology’: Lymphoma Gets Nervous
Further information...
28th September 2010
Dr John Curnow joins Celentyx as Principal Scientist.
Further information...
8th December 2009
Alan Boyd appointed Honorary Professor at the University of Birmingham Medical School.
Further information...
24th August 2009
Celentyx enters into agreement with Meiji Seika Kaisha, Ltd to discover new development paths for Meiji drug candidates using Celentyx’s Novel Clinical Indication Profiling™
Further information...
8th July 2009
Celentyx announces Immuno-Profiling™ collaboration with natural products drug company Hypha Discovery.
Further information...
11th May 2009
Ann Hayes Joins Celentyx Ltd as Chairman of the Board.
Further information...
10th December 2008
Celentyx announces continued collaboration with AMRI.
Further information...
27th October 2008
Celentyx announces collaboration with Alfama Inc.
30th September 2008
Celentyx and AMRI to present data at British Pharmacological Society Winter Meeting 2008
Brighton, UK, 16-18 December, 2008
Further information...
18th July 2008
Celentyx and AMRI present data at Serotonin Club Meeting 2008 in Oxford, UK
3rd January 2008
Celentyx announces collaboration with Schering-Plough
Further information...
12th December 2007
Celentyx secures major funding boost
Further information...
2nd March 2007
Official launch of Celentyx Ltd
Further information...
26th January 2007
Ethical permission granted to Celentyx Ltd for use of human blood cells
13th December 2006
Award of TTF grant to expand operations
17th October 2006
Celentyx Ltd awarded DTI R&D grant
2nd October 2006
First NCIP™ contract with North American pharmaceutical
company